Intravenous inoculation of BCG was found to be both prophylactic and therapeutic in BALB/c mice against challenge with amastigotes of Leishmania donovani. Spleens and livers of mice inoculated with BCG maintained total parasite burdens at significantly lower levels when compared to controls. BCG administered intravenously 14 days prior to and on the same day of protozoan challenge was more protective than vaccine given 30 Leishmaniasis, a disease caused by protozoa of the genus Leishmania Ross, 1903, manifests itself in three major forms: cutaneous, mucocutaneous, and visceral. Each form of leishmaniasis is caused by a different species of Leishmania.
Immunity in leishmaniasis appears to be cellular in nature (9) , although cell-bound antibodies may influence the expression of this cellular response (7, 11, 20) . In man, the induction of cell-mediated immunity depends upon the immunological competence of the host and the virulence of the infectious agent. The more virulent forms of organisms, those causing the most severe and rapidly healing disease, provide the best and most persistent immunity. For example, Leishmania tropica major causes a more severe disease than Leishmania tropica minor. An individual who has recovered from infection withL. tropica major is immune to reinfection with the latter organism; however, the reverse is not true. Individuals who have recovered from infection with L. tropica minor are not immune to infection with L. tropica major. This phenomenon is the basis for the massive vaccination program used in Russia (20, 27, 35) .
To date no attenuated strains ofLeishmania providing adequate protection have been found. In addition, there is no cross immunity between the various forms of leishmaniasis (18, 20, 29, 36, 39) . As a result, leishmaniasis remains a menace in certain countries and continues to be a major world health problem.
Complement-fixing antibodies produced by kala-azar (visceral leishmaniasis) patients are best demonstrated with the use of Mycobacterium antigens (16, 25, 26, 34, 38, 42) . Even though these antibodies have no detectable role in immunity against the disease, the use of Mycobacterium antigen in the complement-fixation test for kala-azar indicates a specific cross-reactivity between members of the protozoan genus Leishmania and the bacterial genus Mycobacterium.
In this paper, we report the effects of inoculation of BALB/c mice with BCG upon the growth ofLeishmania donovani in the spleens and livers of the recipients.
termination of the total parasite burden ofL. donovani-infected tissue was done by the methods suggested by Stauber (40, 41) . A small piece of infected spleen or liver tissue was blotted on a paper towel to remove blood and loose cells. The cut face of the tissue was dabbed lightly on an alcohol-cleaned slide. At least 15 to 25 impression smears were made for each organ assayed. The slide was air-dried, fixed for 10 s with absolute methanol, and stained for 30 to 60 min with Giemsa stain. The impression smears were studied with light microscopy. The ratio of amastigotes/cell nuclei was determined as follows. While the impression smears were being scanned with an oil immersion magnification (x 1,000), a count of the amastigotes and cell nuclei was made. As soon as one of the two counts reached 1,000, the ratio of amastigotes/cell nuclei (LD/CN) was calculated. This ratio, when multiplied by the weight of the organ or tissue (in milligrams) and multiplied by 200,000, gives a value that is considered to be the estimated total parasite burden (TPB), e.g., TPB = (number of amastigotes/ number of cell nuclei) Mice inoculated i.v. with 2.0 x 106 amastigotes had mean spleen parasite burdens of approximately 8.5 x 106 at 30 days p.i. (Fig. 3 ). This parasite burden was maintained over the next 30 days. Animals given 1-log-fewer parasites (2.0 x 10") exhibited mean spleen parasite burdens of approximately 9.0 x 10" at 30 days p.i. This parasite burden gradually increased to 4.0 x 10'i by 60 days p.i. Administration of 1.0 x 107 VU of BCG i.v. 14 days prior to and on the day of protozoan challenge reduced the parasite burdens of the spleens of both groups to prepatent levels. Both groups of infected mice inoculated with BCG had no detectable parasites in their spleens during the 60-day study period. Figure 4 shows the parasite burdens of the livers of both control mice and mice that had been inoculated with BCG. Mice inoculated i.v. The parasite burdens steadily declined to 4.3 x 107 by 60 days p.i. Administering BCG i.v. 14 days prior to and on the day of challenge (2.0 x 10" amastigotes) significantly reduced the parasite burdens (P < 0.01). Three ofthe seven mice that had been given BCG and challenged with 2.0 x 106 amastigotes had reduced parasite burdens of 3.7 x 10". The remaining four mice had parasite burdens that were too low to detect. All mice that had been treated with BCG and challenged with 2.0 x 10" amastigotes had no detectable liver parasites 45 and 60 days p.i. Animals inoculated i.v. with 1-log-fewer amastigotes (2.0 x 108) had liver parasite burdens of 1.3 x 107 at 30 days p.i. The parasite burdens declined to a mean value to 3.5 x 10" by day 45 p.i. and remained at that level for the duration of the experiment. Mice given BCG i.v. and challenged i.v. with 2.0 x 103 amastigotes had reduced parasite burdens at the prepatent level throughout the entire 60-day study period.
Determination and macrophages. It has been shown that administration of BCG to sensitized mice activates macrophages (17) 14 days after administration of BCG may not be cleared from the spleen as effectively as it is in mice that were given the second dose of BCG on the day ofchallenge. The role, production, and effect of soluble mediators produced by sensitized lymphocytes during a cell-mediated immune response has been well established in the literature (8, 15) . The presence and role of soluble mediators produced in response to leishmaniasis has also been reported (7, 9, 10, 43) .
The inoculation of mice with 1.0 x 107 rather than with 1.0 x 106; VU of BCG results in greater protection against subsequent infection withL. donovani. Mackaness and Blanden (33) reported that increasing the number of BCG bacilli administered to guinea pigs and mice intensified their delayed hypersensitivity responses. The enhanced response of animals that were given greater numbers of BCG can be relat6d to the greater number of organisms which survive and proliferate in the host and serve as antigen depots for stimulation of lymphocytes and for production of soluble mediators. In our study of the immunotherapeutic effects of the administration of BCG to mice which had been previously infected with L. donovani, there was no effect upon the liver parasite burdens of mice treated by i.v. The administration of BCG to mice infected with the lower number of protozoa effectively controlled the spleen parasite burdens among them. The failure of mice infected with larger numbers of amastigotes to respond as well to BCG therapy compared to those which had been injected with the smaller number of protozoa may result from immunological tolerance, antigenic competition, or paralysis of the reticuloendothelial system. This supposition is supported by the results of other workers. Adler (1) reported that hamsters infected with L. donovani for an extended length oftime were unable to reject skin homografts, indicating an alteration of the cell-mediated mechanism in the animal. Bryceson et al. (9, 11) (2) reported that the bacterial adjuvants mentioned above interfere with the migration of T-lymphocytes into lymph nodes, thus interfering with the induction phase of the delayed response. This may explain, in part, the increase in severity of infection in adjuvant-treated and infected guinea pigs, but it does not explain why the guinea pigs were able to exhibit a delayed-type response to the leishmanin antigen.
The route of injection of BCG is of major importance for the protection of mice inoculated with L. donovani. BALB/c mice that had been treated by i.v. injection of BCG and challenged i.v. with amastigotes had fewer spleen and liver parasites than did those mice that had been inoculated i.p. with BCG and challenged i.v. (Fig. 7 and 8) . Larson et al. (30, 31) reported that administration of BCG to mice will protect against challenge with Friend Disease virus if the BCG is given via the same route as the challenge dose. The reasons for this are not clear, but one obvious explanation is that the distribution of acid-fast bacilli in the host differs as the route of administration of BCG is varied. The small granulomata (19) important to the activity of nonspecific resistance will, therefore, vary in their distribution. It is important that the reticuloendothelial cells stimulated with BCG be in the same area as those affected by the parasite.
There are at least three mechanisms by which BCG immunization produces its effect. The granulomata produced by administration of BCG are so structured as to be an ideal site for the production of soluble mediators. The central area of the granulomata contains actively metabolizing bacilli, and these release products that serve to stimulate lymphocytes in the peripheral area. The stimulation results in the synthesis of soluble mediators by the sensitized lymphocytes to perform a multitude of activities. Cytotoxic lymphocytes capable of destroying cells containingL. donovani could also be produced at granulomata sites. The findings of Evans and Alexander (17) , Krahenbuhl and Remington (28) , and Hibbs et al. (22, 24) The reduced clearance of protozoans from the liver cells of infected mice treated with BCG could thus be explained, since the liver is not an immunocompetent organ (37) . The spleen, however, has an abundance of T-cells and macrophages possessing the capacity to affect cell-mediated immunity.
